Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

van de Donk, Niels ^{[1
]}

Moreau, Philippe ^{[2
]}

Garfall, Alfred ^{[3
]}

Bhutani, Manisha ^{[4
]}

Oriol, Albert ^{[5
,6
]}

Nooka, Ajay ^{[7
]}

Martin, Thomas ^{[8
]}

Rosinol, Laura ^{[9
]}

Mateos, Maria-Victoria ^{[10
]}

Bahlis, Nizar ^{[11
]}

Popat, Rakesh ^{[12
]}

Besemer, Britta ^{[13
]}

Martinez Lopez, Joaquin ^{[14
]}

Krishnan, Amrita ^{[15
]}

Delforge, Michel ^{[16
]}

Trancucci, Danielle ^{[17
]}

Verona, Raluca ^{[18
]}

Stephenson, Tara ^{[18
]}

Chastain, Katherine ^{[17
]}

Sidana, Surbhi ^{[19
]}

机构：

[1] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[2] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[4] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[6] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[10] Univ Hosp Salamanca IBSAL CIC CIBERONC, Salamanca, Spain

[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[12] NHS Fdn Trust, Univ Coll London Hosp, London, England

[13] Univ Tubingen, Tubingen, Germany

[14] Hematol Hosp 12 Octubre, Madrid, Spain

[15] City Hope Comprehens Canc Ctr, Duarte, CA USA

[16] Univ Leuven, Leuven, Belgium

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Spring House, PA USA

[19] Stanford Univ, Sch Med, Stanford, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

relapsed/refractory multiple myeloma; bispecifics; multiple myeloma; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-163

引用

页码：S477 / S478

页数：2

共 50 条

[1] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Donk, Van De N. W.
Moreau, P.
Garfall, A. L.
Bhutani, M.
Oriol, A.
Nooka, A. K.
Martin, T. G.
Rosinol, L.
Mateos, M. -V.
Bahlis, N.
Popat, R.
Besemer, B.
Lopez, Martinez J.
Krishnan, A.
Delforge, M.
Trancucci, D.
Verona, R., I
Stephenson, T.
Chastain, K.
Sidana, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
[3] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[4] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[5] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
Nooka, Ajay K.
Moreau, Philippe
Usmani, Saad Zafar
Garfall, Alfred L.
Van De Donk, Niels W. C. J.
San-Miguel, Jesus F.
Oriol Rocafiguera, Albert
Chari, Ajai
Karlin, Lionel
Mateos, Maria-Victoria
Popat, Rakesh
Martinez, Joaquin
Sidana, Surbhi
Trancucci, Danielle
Verona, Raluca
Girgis, Suzette
Uhlar, Clarissa
Stephenson, Tara
Banerjee, Arnob
Krishnan, Amrita Y.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Garfall, Alfred L.
Usmani, Saad Z.
Mateos, Maria-Victoria
Nahi, Hareth
van de Donk, Niels W. C. J.
San-Miguel, Jesus F.
Rocafiguera, Albert Oriol
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Krishnan, Amrita
BLOOD, 2020, 136
[7] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Popat, Rakesh
Usmani, Saad Z.
Garfall, Alfred
van de Donk, Niels
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar
Moreau, Philippe
Besemer, Britta
Martinez-Lopez, Joaquin
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
[8] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Moreau, Philippe
Usmani, Saad Z.
Garfall, Alfred L.
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas
Rosino, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martínez-López, Joaquín
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca I.
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa M.
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita Y.
BLOOD, 2021, 138
[9] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Garfall, Alfred L.
Nooka, Ajay K.
van de Donk, Niels W. C. J.
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S548 - S548
[10] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Krishnan, Amrita Y.
Garfall, Alfred L.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Karlin, Lionel
Benboubker, Lotfi
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →